Top Markets
#1 Siren Siren +35.55%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.06%
#3 PulseChain PulseChain +17.72%
#4 Ribbita by Virtuals Ribbita by Virtuals +17.03%
#5 OpenEden OpenEden +16.58%
#6 Cysic Cysic +16.56%
#7 BasedHype BasedHype +15.88%
#8 The Grays Currency The Grays Currency +15.71%
#9 KUB Coin KUB Coin +15.65%
#10 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +15.50%
Coin of the day
Siren Siren
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Celyad Oncology S.A. Celyad Oncology S.A.

Celyad Oncology S.A.

CYAD
Kedudukan dalam Saham #30831
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to... Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
Harga Saham
$0.343985
Modal Pasaran
$15.40M
Perubahan (1 hari)
3.94%
Perubahan (1 tahun)
-25.19%
Negara
BE
Perdagangan Celyad Oncology S.A. (CYAD)

Kategori

Healthcare
Pendapatan untuk Celyad Oncology S.A. (CYAD)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Celyad Oncology S.A., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Celyad Oncology S.A. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE